These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31185876)

  • 1. Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicine.
    Sleeboom-Faulkner M
    Soc Stud Sci; 2019 Jun; 49(3):355-380. PubMed ID: 31185876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insurance systems and reimbursement concerning research and development of regenerative medicine in Japan.
    Okada K; Miyata T; Sawa Y
    Regen Med; 2017 Mar; 12(2):179-186. PubMed ID: 28244828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.
    Takashima K; Morrison M; Minari J
    Stem Cell Reports; 2021 Jun; 16(6):1425-1434. PubMed ID: 34019814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US FDA outreach to the regenerative medicine community: challenges and opportunities.
    Whittlesey KJ; Witten C
    Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regenerative medicine in Europe: global competition and innovation governance.
    Hogarth S; Salter B
    Regen Med; 2010 Nov; 5(6):971-85. PubMed ID: 21082895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
    Ginty PJ; Rayment EA; Hourd P; Williams DJ
    Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regenerative medicine in India: trends and challenges in innovation and regulation.
    Tiwari SS; Raman S; Martin P
    Regen Med; 2017 Oct; 12(7):875-885. PubMed ID: 29111891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulating cell-based regenerative medicine: the challenges ahead.
    Ali RR; Hollander AP; Kemp P; Webster A; Wilkins MR
    Regen Med; 2014 Jan; 9(1):81-7. PubMed ID: 24351008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What can be learnt from the Japanese regulatory approach to tissue engineered products?
    Brévignon-Dodin L; Livesey F
    Regen Med; 2007 Nov; 2(6):967-71. PubMed ID: 18034634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purity and the dangers of regenerative medicine: regulatory innovation of human tissue-engineered technology.
    Faulkner A; Kent J; Geesink I; FitzPatrick D
    Soc Sci Med; 2006 Nov; 63(9):2277-88. PubMed ID: 16905231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japan's patent issues relating to life science therapeutic inventions.
    Tessensohn JA
    Expert Opin Ther Pat; 2014 Sep; 24(9):953-7. PubMed ID: 25089628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
    Plagnol AC; Rowley E; Martin P; Livesey F
    Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familiarity and prudence of the Japanese public with research into induced pluripotent stem cells, and their desire for its proper regulation.
    Shineha R; Kawakami M; Kawakami K; Nagata M; Tada T; Kato K
    Stem Cell Rev Rep; 2010 Mar; 6(1):1-7. PubMed ID: 20091428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downgrading of regulation in regenerative medicine.
    Sipp D; Sleeboom-Faulkner M
    Science; 2019 Aug; 365(6454):644-646. PubMed ID: 31416952
    [No Abstract]   [Full Text] [Related]  

  • 15. Protecting methods for treatment related to regenerative medicine and gene therapy in Japan.
    Kaneshiro K; Masuda S; Tanaka Y; Tamai K
    Nat Biotechnol; 2004 Mar; 22(3):343-5. PubMed ID: 14990960
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparative analysis of attitudes toward stem cell research and regenerative medicine between six countries - A pilot study.
    Shineha R; Inoue Y; Yashiro Y
    Regen Ther; 2022 Jun; 20():187-193. PubMed ID: 35620641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory perspectives of Japan.
    Kusakabe T
    Biologicals; 2015 Sep; 43(5):422-4. PubMed ID: 26028474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balancing Safety and Efficacy With Early Availability in the Regulation of Regenerative Medicine Product.
    Fujiwara Y; Maruyama Y; Honda F
    Clin Pharmacol Ther; 2021 May; 109(5):1182-1185. PubMed ID: 32979224
    [No Abstract]   [Full Text] [Related]  

  • 19. Regenerative medicine: a snapshot of the current regulatory environment and standards.
    Messenger MP; Tomlins PE
    Adv Mater; 2011 Mar; 23(12):H10-7. PubMed ID: 21433095
    [No Abstract]   [Full Text] [Related]  

  • 20. The pluralization of the international: Resistance and alter-standardization in regenerative stem cell medicine.
    Rosemann A; Chaisinthop N
    Soc Stud Sci; 2016 Feb; 46(1):112-39. PubMed ID: 26983174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.